Cytespace Research Private Limited Revenue and Competitors

Bangalore, India

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Cytespace Research Private Limited's estimated annual revenue is currently $16.2M per year.(i)
  • Cytespace Research Private Limited's estimated revenue per employee is $135,000

Employee Data

  • Cytespace Research Private Limited has 120 Employees.(i)
  • Cytespace Research Private Limited grew their employee count by -6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$80.3M47627%N/AN/A
#2
$41.6M280-4%N/AN/A
#3
$35.2M23730%N/AN/A
#4
$75.1M4455%N/AN/A
#5
$34.3M2317%N/AN/A
#6
$89.8M52417%$13.2MN/A
#7
$133.1M7047%N/AN/A
#8
$142.7M75519%N/AN/A
#9
$44.3M2985%N/AN/A
#10
$170.9M9047%N/AN/A
Add Company

Cytespace Research is an exciting organization in the emerging market Clinical Research Site Solutions space. Cytespace has a unique and strong leadership team with over 100 person-years of experience in the clinical research field. and offers a range of site services to bio-pharmaceutical sponsors and CROs. Our strong relationships with sites, vision of scale, technology usage, strong training and people development methodology, and a cost-effective process-based approach are some of the factors that set us apart from the pack. The Asia/ Africa region has a number of advantages that make it a highly attractive market for clinical trials, with a huge growth potential. However, the lack of quality processes at the site, low standardization, infrastructure issues and high attrition rates of site staff are major stumbling blocks. Cytespace?s scalable model takes these challenges head-on and improves the site performance predictability and delivers better clinical trial conduct for customers.

keywords:N/A

N/A

Total Funding

120

Number of Employees

$16.2M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.2M12036%N/A
#2
N/A12071%N/A
#3
$9.9M120-4%N/A
#4
N/A120107%N/A
#5
$9M12022%N/A